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 CURRENTOPINION Challenges and needs in experimental therapies for
multiple sclerosis
Andreas Lutterotti
Purpose of review
Despite dramatic advances in the treatment of people with multiple sclerosis over the last decade, several
unmet medical needs still remain and should be approached with new compounds in experimental clinical
trials. The prerequisites for successful clinical trials in multiple sclerosis have changed considerably over
time and activities have started to improve clinical development of new drugs in several aspects including
trial designs, patient selection and outcome parameters. This review will address some of the challenges in
early experimental trials in multiple sclerosis and recent approaches in the field.
Recent findings
Highly intensive treatment regimens like autologous hematopoietic stem cell transplantation provide
evidence for sustained long-term treatment effects in multiple sclerosis patients. Several different approaches
towards neuroprotection and remyelination have entered the clinical phase and demonstrated that
stabilization, even improvement of disability is achievable in short-term studies.
Summary
New therapeutic strategies have entered the clinic with the prospects of long-term efficacy and enduring
effects on disability progression.
Keywords
experimental therapy, multiple sclerosis, neuroprotection, outcome measure, trial
INTRODUCTION
Over the last decade we have seen a tremendous
increase in the number of approved therapies for
multiple sclerosis and these have changed the
management of the disease considerably. As a
downside of the development, patients have to
face increasing and sometimes even severe risks
from side effects of highly active disease-modify-
ing therapies. Nevertheless, early treatment initia-
tion has become standard-of-care even in patients
with their first manifestation of the disease called
clinically isolated syndrome. Recent adaptations
in the diagnostic criteria for multiple sclerosis
facilitate a definite diagnosis of multiple sclerosis
in many patients at this stage and provide the
basis for a large spectrum of approved therapies
to be initiated [1].
The increasing efficacy of immune therapies
fostered new developments in the definition of
treatment responses. The term of no evident dis-
ease activity (NEDA) has been proposed,
which combines disease-free status by clinical
parameters (relapses and disability progression)
and new lesion development on MRI [2]. A
treat-to-target approach using NEDA as target
endpoint has been proposed for the management
of multiple sclerosis and this concept will clearly
set a new benchmark for novel disease-modifying
drugs seeking approval for treatment of multiple
sclerosis [3].
In the therapeutic management of multiple
sclerosis, there is a distinction between the impact
of a therapy on inflammatory disease activity,
which is generally measured by the occurrence
of relapses or the development of new or
enlarging lesion on the MRI of the brain and
spinal cord and the impact of the treatment
on neurodegenerative disease processes, which
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are measured by disability progression and brain
atrophy on MRI [4
&
]. Novel highly active immune
therapies have demonstrated a greater effect on
both reduction of inflammatory disease activity
as well as reducing the progression of the disease.
Recently, ocrelizumab a monoclonal antibody
against CD20 on B cells leading to long-term deple-
tion of these cells, was the first disease-modifying
therapy to be approved for treatment of primary
progressive disease [5].
Still, several unmet medical needs remain in
the therapeutic management of multiple sclerosis
that should be approached by novel experimental
therapies. First, there is a need for improvements
in safety profiles that have to go along with a
high efficacy of new treatments. Second, new
therapies should aim to target the main patho-
genic mechanisms with high specificity and ide-
ally restore the deleterious immune response
without altering the ‘normal’ functions of the
immune system. Third, there is need for neuro-
protective therapies and approaches that facilitate
remyelination of inflammatory lesions in the
brain and spinal cord. Fifth, there is a need for
well tolerated treatments to improve important
symptoms in multiple sclerosis such as fatigue,
gait disturbance, ataxia, spasticity and others.
Finally, all of the above named approaches should
be selected for individual patients using objective
parameters, thus providing personalized treat-
ment decisions.
Here we will review some of the challenges and
pitfalls in experimental therapies for multiple scle-
rosis and focus on the early phase of clinical devel-
opment in phase I and phase II trials.
CHALLENGES AND PITFALLS IN
EXPERIMENTAL THERAPIES FOR
MULTIPLE SCLEROSIS
Over the last 50 years, the efficiency of pharmaceu-
tical development has declined constantly, a phe-
nomenon called Erooms law [6]. Pharmaceutical
development is usually split in the preclinical phase
and the clinical phase, the latter starting from phase
I throughout phase III/IV clinical trials. Considering
the advancesmade in high throughput technologies
at different levels, that is, in the preclinical phase, it
becomes clear that the translation from preclinical
to the clinical phase, that is, phase I/II clinical trials,
remain the main bottleneck and most critical phase
of pharmaceutical development [7]. In fact, 9 out of
10 novel drug candidates fail at this stage.
Thus, several critical points have to be consid-
ered during early phase clinical development for
multiple sclerosis. The main aims of early phase I/
II clinical trials are to establish the safety and toler-
ability and to provide a proof-of-concept for the
efficacy of the investigational drug. Whenever pos-
sible efforts should be made to provide a proof-of-
mechanism of the approach to confirm the pre-
sumed mode of action (MoA) of the therapy. This
requires a solid understanding of the presumedMoA
and the technologies to proof it with biomarkers of
treated patients.
Selection of the most appropriate patients for
the specific therapeutic approach is crucial in the
early phase clinical development. For novel
immune therapies, the recruitment of multiple scle-
rosis patients to phase II clinical trials is increasingly
challenged by the augmenting number of approved
therapies. One also has to consider that the observed
disease activity in clinical trials has changed over
time, which is reflected by the strong differences in
the on-treatment relapse rates in clinical trials per-
formed during the last decade [8
&
]. The key data used
for calculation of effect sizes, patient numbers and
observation periods for a specific outcome parame-
ter have to reflect such developments. For example,
the annualized relapse rate (ARR) is frequently used
as outcome parameter for inflammatory disease
activity in clinical trials and recent phase III trials
reported ARR less then 0.3 even in the placebo-
treated patients [9]. In particular, for therapies aim-
ing at neuroprotection incorrect estimation of dis-
ability progression in the trial population has
contributed to the failure of proof-of-concept
(PoC) trials [10].
One of the most important challenges in exper-
imental therapies in multiple sclerosis is the choice
of clinical and imaging-based outcome parameters
that allow for the precise quantification of inflam-
matory disease activity and changes in disability
KEY POINTS
 Changing paradigms in the management of multiple
sclerosis challenge current procedures of experimental
clinical trials.
 Developments of innovative trial designs, sensitive
outcome measures and novel parameters for patient
stratification are needed to improve clinical
development for new therapies.
 Highly intensive therapeutic approaches, like
autologous hematopoietic stem cell transplantation have
demonstrated enduring efficacy and promise long-term
remission of disease activity and even improvement
of disability.
 New therapeutic strategies targeting neuroprotection
and remyelination have achieved promising results in
early-phase clinical trials.
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progression or neurodegeneration [4
&
]. Relapses and
lesion development on MRI are the main clinical
and imaging parameters used for assessment of
inflammatory disease activity whereas disability
progression and brain atrophy on MRI are the most
widely used parameters to reflect neurodegenera-
tion. Novel disease-modifying therapies aim at
preventing both, inflammation and neurodegener-
ation but an increasing number of substances are
tested as purely neuroprotective agents. Particularly,
early phase experimental therapies are often limited
in the duration of the trial and the number of
participants. Thus, they have to rely on outcome
parameters that are sensitive to changes within
those restrictions and provide a surrogate for mid-
term and long-term effects of the intervention. In
early phase II trials, imaging-based parameters are
frequently used as surrogate to follow inflammatory
disease activity and/or neurodegeneration. How-
ever, with recent highly active immune therapies
and novel approaches for neuroprotection and
remyelination, there is a fundamental change in
these concepts and a clear need for sensitive param-
eters able to reflect even an improvement in disabil-
ity. The currently used clinical rating scale to assess
disability in multiple sclerosis, the Expanded Dis-
ability Rating Scale (EDSS), is largely influenced
by walking disability and does not reflect changes
in other functional systems (i.e. motor function
of upper limb, coordination, fatigue) once an
impairment in gait has been reached [11]. Outcome
measures based on the EDSS or a composite of EDSS
and other measures of the function of the upper
extremity (Nine-hole-peg test), walking speed
(Timed 25-foot walk test) and cognition (Paced
auditory serial attention test or symbol digit modal-
ities test) are, therefore, insensitive to disability out-
comes once patients have a reached a certain level of
gait impairment. As an example, a trial of natalizu-
mab in secondary progressive multiple sclerosis
failed in its primary endpoint, despite a clinical
significant improvement in the function of the
upper extremity (9-HPT) in the natalizumab-treated
group (Steiner et al., 2016). Several groups have
started to adapt clinical measures of disability pro-
gression and improvement, but further efforts are
needed to improve the validity and reliability of
clinical outcome measures and test them in innova-
tive trial designs.
EXPERIMENTAL IMMUNE THERAPIES
Recent therapeutic developments have focused on
therapies with a long-term impact on the disease.
Indeed, highly active therapies like Aletuzumab,
Ocrelizumab and Cladribine have shown to
effectively reduce disease activity and in some
patients even with a longer lasting effect, but still
only 30–50% of patients reach complete freedom of
disease activity (NEDA) at 2 years [12
&
,13].
In the last 24 months, one experimental thera-
peutic approach has particularly impacted the field,
which is autologous hematopoietic stem cell trans-
plantation. Themain concept behind the approach is
that the intense immunosuppression followed by
infusion of autologous hematopoietic stem cells
incites a complete replacement of the ‘autoreactive’
immune system with a new and tolerant immune
system [14
&
]. In fact, there is experimental data sup-
porting the concept of a complete renewal of the
adaptive immune response [15]. Several recent trials
have demonstrated very good efficacy of the treat-
ment and corroborated a long-lasting reduction or
even complete prevention of new disease activity
together with improvements in disability [13,16–
20,21
&
,22]. Up to 70% of multiple sclerosis patients
treatedbyautologoushaematopoietic stemcell trans-
plant (aHSCT) reach aNEDAendpoint at 5 years, thus
being far more effective compared with approved
therapies [12
&
]. Still, it has to be considered that
the study populations from pivotal phase III clinical
trials of approved therapies are not directly compa-
rablewith the smallerphase II studiesonaHSCTanda
direct comparison of the efficacy and long-term
effects of the treatments within controlled clinical
trials is warranted. Nevertheless, a recent retrospec-
tive analysis of multiple sclerosis patients treated by
aHSCT demonstrated efficacy for prevention of fur-
ther accumulation of disability, and some patients
even had an improvement in disability, despite the
fact, that most patients already had reached higher
disability scores at the time of aHSCT [21
&
].
EXPERIMENTAL THERAPIES TARGETING
NEUROPROTECTION
Despite some successes in efficacy of anti-inflamma-
tory immune therapies for patients with progressive
multiple sclerosis, there is a strong need for agents
with neuroprotective properties. Several different
pathways are described to be involved in neuro-
degeneration in multiple sclerosis, including loss
of trophic support in demyelinated axons and expo-
sure to inflammatory mediators, reactive oxygen
species, mitochondrial dysfunction and changes
in the expression sodium channels, which are
reviewed elsewhere in more detail [23]. Different
available drugs, approved for various indications,
target many of these mechanisms and have thus a
potential capacity for neuroprotection in multiple
sclerosis patients [24]. Such a repurposing of drugs is
an efficient way for development of neuroprotective
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agents and different academic groups have followed
some of these approaches [25]. A recent phase II
study tested simvastatin in secondary progressive
multiple sclerosis [26,27]. The simvastatin-treated
group had a 43% reduction in whole-brain atrophy
and a slower worsening of disability measured by
EDSS. In a secondary analysis of the trial population,
there was evidence for a positive effect of simva-
statin on frontal lobe function and physical quality-
of-life measurement [26]. Biotin was tested in pro-
gressive multiple sclerosis patients in a phase II
study using as a novel trial endpoint, which is the
proportion of patients with reversal of disability at
month 9 confirmed at month 12 [28
&
]. A total of
12.6% of high-dose biotin-treated patients achieved
the primary endpoint versus none of the placebo
group. Following these positive results, a phase III
trial in progressive multiple sclerosis patients is
ongoing. Phenytoin was tested as neuroprotective
agent in a phase II trial in patient with optic neuritis
using optical coherence spectroscopy (OCT) to mea-
sure the retinal nerve fibre layer thickness (RNFL) of
the affected eye at 6 months as primary outcome
[29]. Among 86 recruited patients, there was a 30%
reduction in the extent of RNFL loss with phenytoin
compared with placebo. Ibudilast a phosphodiese-
terase and macrophage inhibitory factor inhibitor,
was tested in a randomized, placebo-controlled
phase II clinical trial in 255 progressive multiple
sclerosis patients using the change in brain atrophy
onMRI, measured by brain parenchymal fraction, as
primary outcome parameter. The results were pre-
sented at the Congress of the European Committee
for Treatment and Research in multiple sclerosis
(ECTRIMS, 2017) and the study met the primary
endpoint with a 48% reduction in whole brain
atrophy after 96 weeks in the ibudilast-treated group
[30]. Erythropoietin (EPO), is part of a endogenous
neuroprotective system in the brain, with antiapop-
totic, anti-inflammatory and antioxidative proper-
ties and has been used successfully in a phase II trial
in patients with optic neuritis as well as patients in
chronic progressive multiple sclerosis patients
[31,32]. A recent trial, however, failed to show effi-
cacy of EPO in reducing disability progression mea-
sured by a composite measure of maximum gait
distance, hand dexterity and cognition from base-
line to 24 weeks in progressive multiple sclerosis
patients [33].
EXPERIMENTAL THERAPIES TARGETING
REMYELINATION
A few new approaches that target remyelination in
multiple sclerosis have entered the clinical phase
[34,35]. LINGO1 is a glycoprotein expressed on
neurons and oligodendrocyte precursor cells and
has been identified as important negative regulator
of remyelination. A monoclonal antibody (Opicinu-
mab) blocking LINGO1 was developed to facilitate
remyelination inmultiple sclerosis lesions. Although
initial PoC trials did not meet the expected results,
posthoc analyses of the trials suggested positive
effects in a subgroup of patients with short-disease
duration and defined MRI imaging characteristic on
magnetization transfer ratio and diffusion weighted
images [36,37]. A ongoing phase II clinical trial will
assess the efficacy of opicinumab to improve clinical
disability in multiple sclerosis patients on stable
immune therapy. Another approach targeting
remyelination by stimulating the differentiation of
oligodendrocyte precursor cells was discovered in a
high throughput approach [38]. In a phase II ran-
domized crossover trial twice daily, clemastine was
compared with placebo in patients with multiple
sclerosis and chronic demyelinating optic neuropa-
thy [39
&
]. The primary endpoint was changed in
latency delay on VEP, which was reduced by
1.9ms/eye in the clemastine-treated group.
CONCLUSION
The last decade has brought incredible achieve-
ments in the treatment of multiple sclerosis, and
new therapeutic concepts targeting NEDA or
improvement of disability are already beginning
to influence the management of multiple sclerosis
patients. Treatment development in multiple scle-
rosis has to tackle several challenges and pitfalls to
successfully pass early phase clinical development
and some trials have already demonstrated how
they can be overcome to provide new therapies
for people with multiple sclerosis.
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